Last reviewed · How we verify
Pegylated interferon beta-1a
Pegylated interferon beta-1a works by stimulating the body's immune system to fight multiple sclerosis.
Pegylated interferon beta-1a works by stimulating the body's immune system to fight multiple sclerosis. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | Pegylated interferon beta-1a |
|---|---|
| Sponsor | Cinnagen |
| Drug class | Interferon |
| Target | IFNAR |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
It does this by increasing the production of interferon beta, which helps to reduce inflammation in the central nervous system. This can slow the progression of multiple sclerosis and reduce the frequency of relapses.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
- Depression
- Anxiety
Key clinical trials
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- Plegridy Satisfaction Study in Participants (PHASE4)
- Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis (PHASE3)
- Plegridy Observational Program
- Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis
- The Containing Coronavirus Disease 19 (COVID-19) Trial (PHASE3)
- Comparative Clinical Trial to Evaluate Efficacy, Safety and Tolerance of BCD-054 and Avonex® for Treatment of Patients With Remitting-relapsing Multiple Sclerosis (PHASE2, PHASE3)
- Multiple Sclerosis: Chi3L1 and Treatment Efficacy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |